Christopher Peetz, Chief Executive Officer of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), sold 20,000 shares of the company’s common stock for a total of approximately $2.4 million on July 6, 2026. The sales followed the exercise of employee stock options. The timing comes as MIRM stock has surged 155% over the past year and currently trades near its 52-week high of $129. According to InvestingPro analysis, the stock appears overvalued at current levels.
The shares were sold at prices ranging from $121.11 to $124.94 per share. Specifically, 12,134 shares were sold at a weighted average price of $121.65, 4,181 shares at $122.34, 1,975 shares at $123.74, and 1,710 shares at $124.79. These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Peetz on March 2, 2026. An InvestingPro tip notes the stock’s RSI suggests overbought territory—one of 16 exclusive ProTips available to subscribers, along with comprehensive Pro Research Reports covering MIRM and 1,400+ US equities.
Prior to the sales, Mr. Peetz acquired 20,000 shares of Mirum Pharmaceuticals common stock by exercising fully vested employee stock options. These options had an exercise price of $2.936 per share, representing a total acquisition value of $58,720. The options are set to expire on March 11, 2029.
Following these transactions, Mr. Peetz directly holds 194,309 shares of Mirum Pharmaceuticals common stock. Additionally, he indirectly holds 187,500 shares through The Peetz Family Trust.
The transactions were reported in a filing with the Securities and Exchange Commission on July 8, 2026.Mirum PharmaceuticalsFollowAnalyze MIRMIncluded in our AI-picked strategies·Review strategies128.57▲+0.26(+0.20%)Closed·15:59:59·USD126.09▼-2.48(-1.93%)After Hours·17:39:031D1W1M6M1Y5YMaxCreated with Highcharts 11.4.814:0015:0016:0017:0018:0019:00122124126128Analyze MIRMIn other recent news, Mirum Pharmaceuticals announced the pricing of $600 million in convertible senior notes due 2032, with a 0.00% interest rate, to be settled on May 15. This move follows the company’s acquisition of zilurgisertib from Incyte, which was highlighted at the ENDO conference. Citizens raised its price target for Mirum Pharmaceuticals to $146, maintaining a Market Outperform rating, and identified the drug as a $200 million opportunity. H.C. Wainwright reiterated a Buy rating with a $185 price target, commenting on interim data from the ongoing Phase 2 PROGRESS study for the treatment of fibrodysplasia ossificans progressiva.
Additionally, Wolfe Research initiated coverage on Mirum with an outperform rating and a $145 price target, projecting Livmarli’s peak worldwide sales to reach approximately $940 million. Citizens also maintained its Market Outperform rating with a $140 price target, citing upcoming late-stage clinical readouts. These developments reflect growing interest and confidence in Mirum Pharmaceuticals’ pipeline and strategic initiatives.